Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets specific breast cancer mutation

NCT ID NCT04524000

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing the safety and effectiveness of a two-drug combination (alpelisib and fulvestrant) for Japanese men and postmenopausal women with a specific type of advanced breast cancer. The cancer must have a PIK3CA mutation and have worsened after standard hormone therapy. The goal is to see if this combination can help control the cancer's growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 464 8681, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4668560, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4678602, Japan

  • Novartis Investigative Site

    Kashiwa, Chiba, 2778577, Japan

  • Novartis Investigative Site

    Isehara, Kanagawa, 259-1193, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 241-8515, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 9808574, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 5400006, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 5418567, Japan

  • Novartis Investigative Site

    Suita, Osaka, 565 0871, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, 1138677, Japan

  • Novartis Investigative Site

    Koto Ku, Tokyo, 135 8550, Japan

  • Novartis Investigative Site

    Meguro-ku, Tokyo, 152-8902, Japan

  • Novartis Investigative Site

    Kumamoto, 860-8556, Japan

  • Novartis Investigative Site

    Niigata, 951-8566, Japan

Conditions

Explore the condition pages connected to this study.

ADVANCED BREAST CANCER